Lerman Hedva, Metser Ur, Grisaru Dan, Fishman Ami, Lievshitz Gennady, Even-Sapir Einat
Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizman Street, Tel-Aviv 64239, Israel.
J Nucl Med. 2004 Feb;45(2):266-71.
The purpose of the study was to assess physiologic endometrial (18)F-FDG uptake during the 4 phases of the menstrual cycle and to differentiate between physiologic and malignant endometrial uptake.
Endometrial (18)F-FDG uptake, expressed as standardized uptake value (SUV), was measured on PET/CT images of 285 consecutive female patients, of whom 246 (112 premenopausal and 134 postmenopausal) had no known gynecologic malignancy and 39 (14 premenopausal and 25 postmenopausal) had cervical, endometrial, or ovarian cancer.
Two peaks of increased endometrial (18)F-FDG uptake were identified during the 4-phase cycle. The mean SUVs were 5 +/- 3.2 and 3.7 +/- 0.9 in menstruating and ovulating patients, respectively, and 2.6 +/- 1.1 and 2.5 +/- 1.1 in patients in the proliferative and secretory phases, respectively. The mean endometrial SUV in postmenopausal patients not receiving hormonal therapy was 1.7 +/- 0.5. Oligomenorrhea and benign endometrial abnormalities were associated with increased (18)F-FDG uptake. Neither contraceptives nor hormonal therapy was associated with a significant increase in endometrial uptake. In addition to the increased tumor uptake measured in patients with cervical cancer (14.9 +/- 7.3 in postmenopausal patients and 12.2 +/- 6.6 in premenopausal patients), increased uptake was also found in the adjacent endometrium, although it appeared normal on CT (4.8 +/- 2 in premenopausal patients and 4.7 +/- 2.8 in postmenopausal patients). Increased ovarian (18)F-FDG uptake was detected in 7 patients with ovarian cancer (9.1 +/- 4) and in 21 premenopausal patients without known ovarian malignancy (5.7 +/- 1.5, P < 0.01), of whom 15 were at mid cycle and 3 reported oligomenorrhea. An ovarian SUV of 7.9 separated benign from malignant uptake with a sensitivity of 57% and a specificity of 95%.
In premenopausal patients, normal endometrial uptake of (18)F-FDG changes cyclically, increasing during the ovulatory and menstrual phases. Increased uptake in the endometrium adjacent to a cervical tumor does not necessarily reflect endometrial tumor invasion. Increased ovarian uptake in postmenopausal patients is associated with malignancy, whereas increased ovarian uptake may be functional in premenopausal patients.
本研究的目的是评估月经周期4个阶段子宫内膜的生理性(18)F-FDG摄取情况,并区分生理性和恶性子宫内膜摄取。
在285例连续女性患者的PET/CT图像上测量子宫内膜的(18)F-FDG摄取,以标准化摄取值(SUV)表示,其中246例(112例绝经前和134例绝经后)无已知妇科恶性肿瘤,39例(14例绝经前和25例绝经后)患有宫颈癌、子宫内膜癌或卵巢癌。
在4个阶段的周期中发现子宫内膜(18)F-FDG摄取增加有两个峰值。月经期和排卵期患者的平均SUV分别为5±3.2和3.7±0.9,增殖期和分泌期患者的平均SUV分别为2.6±1.1和2.5±1.1。未接受激素治疗的绝经后患者的平均子宫内膜SUV为1.7±0.5。月经过少和良性子宫内膜异常与(18)F-FDG摄取增加有关。避孕药和激素治疗均未与子宫内膜摄取显著增加相关。除了在宫颈癌患者中测量到的肿瘤摄取增加(绝经后患者为14.9±7.3,绝经前患者为12.2±6.6)外,在相邻子宫内膜中也发现摄取增加,尽管其在CT上看起来正常(绝经前患者为4.8±2,绝经后患者为4.7±2.8)。在7例卵巢癌患者(9.1±4)和21例无已知卵巢恶性肿瘤的绝经前患者(5.7±1.5,P<0.01)中检测到卵巢(18)F-FDG摄取增加,其中15例处于月经周期中期,3例报告月经过少。卵巢SUV为7.9可区分良性和恶性摄取,敏感性为57%,特异性为95%。
在绝经前患者中,正常子宫内膜对(18)F-FDG的摄取呈周期性变化,在排卵期和月经期增加。宫颈癌旁子宫内膜摄取增加不一定反映子宫内膜肿瘤侵犯。绝经后患者卵巢摄取增加与恶性肿瘤有关,而绝经前患者卵巢摄取增加可能是功能性的。